

# Giuseppe Giaccone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4800679/publications.pdf>

Version: 2024-02-01

562  
papers

56,406  
citations

1040

113  
h-index

1527

218  
g-index

577  
all docs

577  
docs citations

577  
times ranked

42561  
citing authors

#	ARTICLE	IF	CITATIONS
1	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 39-51.	0.5	3,162
2	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2237-2246.	0.8	2,822
3	Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. <i>Journal of Clinical Oncology</i> , 2004, 22, 785-794.	0.8	1,669
4	Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. <i>Journal of Clinical Oncology</i> , 2004, 22, 777-784.	0.8	1,663
5	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	3.8	1,386
6	Targeting the dynamic HSP90 complex in cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 537-549.	12.8	1,306
7	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2010, 11, 521-529.	5.1	1,158
8	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020, 383, 1328-1339.	13.9	959
9	Cell Death Independent of Caspases: A Review. <i>Clinical Cancer Research</i> , 2005, 11, 3155-3162.	3.2	792
10	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013, 8, 823-859.	0.5	792
11	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 6251-6266.	0.8	732
12	Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 442-450.	3.0	647
13	Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8081-8092.	0.8	608
14	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3488-3515.	0.8	606
15	Randomized Phase III Study of Cisplatin With or Without Raltitrexid in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. <i>Journal of Clinical Oncology</i> , 2005, 23, 6881-6889.	0.8	601
16	Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1453-1461.	3.0	550
17	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1204-1223.	0.5	530
18	Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.. <i>Journal of Clinical Oncology</i> , 1998, 16, 145-152.	0.8	493

#	ARTICLE	IF	CITATIONS
19	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3484-3515.	0.8	492
20	American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2121-2127.	0.8	476
21	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 981-988.	5.1	472
22	Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3163-3169.	3.2	470
23	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1997, 15, 2090-2096.	0.8	438
24	A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. <i>Clinical Cancer Research</i> , 2002, 8, 3702-9.	3.2	418
25	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 828-860.	1.2	415
26	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 415-453.	1.2	397
27	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
28	Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. <i>Clinical Cancer Research</i> , 2009, 15, 5267-5273.	3.2	382
29	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S65-S72.	0.5	352
30	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1109-1121.	0.5	342
31	Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group EORTC 08975. <i>Journal of Clinical Oncology</i> , 2003, 21, 3909-3917.	0.8	327
32	Clinical Perspectives on Platinum Resistance. <i>Drugs</i> , 2000, 59, 9-17.	4.9	302
33	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 347-355.	5.1	290
34	Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. <i>Journal of Clinical Oncology</i> , 2008, 26, 983-994.	0.8	287
35	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	7.7	270
36	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 4106-4111.	0.8	265

#	ARTICLE	IF	CITATIONS
37	A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy. <i>Chest</i> , 1994, 106, 320S-323S.	0.4	263
38	Update on Hsp90 Inhibitors in Clinical Trial. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1479-1492.	1.0	263
39	Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. <i>PLoS ONE</i> , 2010, 5, e10630.	1.1	261
40	Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1998, 16, 2133-2141.	0.8	260
41	A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus. <i>Clinical Cancer Research</i> , 2006, 12, 6064-6072.	3.2	260
42	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3825-3831.	0.8	259
43	Global Histone Modifications Predict Prognosis of Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4358-4364.	0.8	257
44	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. <i>Annals of Oncology</i> , 2015, 26, 1421-1427.	0.6	254
45	Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4434-4439.	0.8	252
46	Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15312-15317.	3.3	251
47	Circulating V $\alpha$ 24+ V $\beta$ 11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage. <i>Clinical Immunology</i> , 2001, 100, 144-148.	1.4	250
48	Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. <i>Clinical Cancer Research</i> , 2003, 9, 2316-26.	3.2	248
49	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247
50	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 177-186.	5.1	240
51	Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 1657-1667.	0.8	235
52	Introduction. <i>Lung Cancer</i> , 2003, 41, 1.	0.9	226
53	Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 6698-6702.	3.3	225
54	Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 3400-3408.	0.8	223

#	ARTICLE	IF	CITATIONS
55	Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4481-4486.	0.8	223
56	Drug Resistance-Associated Marker Lrp for Prediction of Response to Chemotherapy and Prognoses in Advanced Ovarian Carcinoma. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1230-1237.	3.0	218
57	Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer) Tj ETQq1 1 0.784314ngBT /Oy	0.7	214
58	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , 2014, 46, 844-849.	9.4	208
59	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3235-3242.	0.8	206
60	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1000-1007.	0.8	206
61	A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, 2321-2329.	1.3	206
62	Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. <i>Journal of Clinical Oncology</i> , 1996, 14, 814-820.	0.8	204
63	Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancer Cells. <i>Cancer Research</i> , 2004, 64, 27-30.	0.4	204
64	Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 1612-1619.	0.8	203
65	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1433-1446.	0.5	201
66	Erlotinib for Frontline Treatment of Advanced Non-“Small Cell Lung Cancer: a Phase II Study. <i>Clinical Cancer Research</i> , 2006, 12, 6049-6055.	3.2	197
67	Apoptosis: target of cancer therapy. <i>Clinical Cancer Research</i> , 2002, 8, 2024-34.	3.2	192
68	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 639-650.	0.5	182
69	Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. <i>British Journal of Cancer</i> , 1998, 77, 621-626.	2.9	174
70	Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 2052-2059.	0.8	174
71	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. <i>International Journal of Cancer</i> , 2005, 117, 883-888.	2.3	173
72	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 666-680.	0.5	170

#	ARTICLE	IF	CITATIONS
73	Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. <i>British Journal of Dermatology</i> , 2002, 147, 598-601.	1.4	168
74	Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. <i>The European Cancer Centre.. Journal of Clinical Oncology</i> , 1997, 15, 317-329.	0.8	167
75	Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). <i>European Journal of Cancer</i> , 2007, 43, 114-121.	1.3	166
76	Thymomas: A review of 169 cases, with particular reference to results of surgical treatment. <i>Cancer</i> , 1986, 58, 765-776.	2.0	165
77	Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 1657-1667.	0.8	162
78	Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 2772-2779.	0.8	160
79	Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. <i>Cancer</i> , 2005, 104, 1794-1807.	2.0	159
80	Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. <i>Annals of Oncology</i> , 2006, 17, 1698-1704.	0.6	156
81	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
82	Selective Decrease in Circulating $\text{V}\alpha 24+\text{V}\beta 11+$ NKT Cells During HIV Type 1 Infection. <i>Journal of Immunology</i> , 2002, 168, 1490-1495.	0.4	155
83	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S73-S80.	0.5	155
84	p53 and chemosensitivity. <i>Annals of Oncology</i> , 1999, 10, 1011-1022.	0.6	151
85	A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2344-2351.	3.2	151
86	Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2100-2105.	0.8	150
87	Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmacology</i> , 2008, 73, 1290-1300.	1.0	149
88	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. <i>Annals of Oncology</i> , 2009, 20, 1674-1681.	0.6	147
89	Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. <i>European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology</i> , 1993, 11, 1230-1240.	0.8	146
90	Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non-Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). <i>Journal of Clinical Oncology</i> , 2000, 18, 2658-2664.	0.8	146



#	ARTICLE	IF	CITATIONS
91	Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. <i>Annals of Oncology</i> , 2000, 11, 385-391.	0.6	143
92	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. <i>International Journal of Cancer</i> , 2006, 118, 209-214.	2.3	142
93	Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2190-2190.	0.8	141
94	CRM1-Mediated Nuclear Export Determines the Cytoplasmic Localization of the Antiapoptotic Protein Survivin. <i>Experimental Cell Research</i> , 2002, 275, 44-53.	1.2	139
95	Differential expression of the c-kit proto-oncogene in germ cell tumours. <i>Journal of Pathology</i> , 1995, 177, 253-258.	2.1	136
96	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 284-290.	3.2	134
97	Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. <i>Blood</i> , 2010, 116, 4848-4858.	0.6	134
98	Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. <i>European Journal of Cancer</i> , 1999, 35, 796-807.	1.3	132
99	Cortisol is transported by the multidrug resistance gene product P-glycoprotein. <i>British Journal of Cancer</i> , 1993, 67, 284-289.	2.9	131
100	Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. <i>Journal of Clinical Oncology</i> , 1997, 15, 2840-2849.	0.8	131
101	A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. <i>Chest</i> , 1994, 106, 320S-323.	0.4	129
102	Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. <i>Journal of Clinical Oncology</i> , 1988, 6, 1264-1270.	0.8	128
103	A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. <i>Annals of Oncology</i> , 2012, 23, 968-973.	0.6	128
104	A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 2601-2606.	0.6	128
105	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892.	3.2	127
106	A phase II study of gemcitabine in patients with malignant pleural mesothelioma. <i>Cancer</i> , 1999, 85, 2577-2582.	2.0	125
107	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth) Tj ETQq1 1 0.784314 rgBT prior chemotherapy and erlotinib. <i>Cancer</i> , 2014, 120, 1145-1154.	2.0	125
108	Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13040-13045.	3.3	123

#	ARTICLE	IF	CITATIONS
109	Thymic Malignancies: From Clinical Management to Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 4820-4827.	0.8	123
110	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 6831-6839.	3.2	123
111	Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2004, 43, 63-69.	0.9	122
112	MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2010, 70, 8288-8298.	0.4	121
113	Second-Line Chemotherapy in Relapsing or Refractory Non-Small-Cell Lung Cancer: A Review. <i>Journal of Clinical Oncology</i> , 2000, 18, 3722-3730.	0.8	119
114	The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S88-S96.	0.5	119
115	Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. <i>European Journal of Cancer</i> , 2010, 46, 340-347.	1.3	116
116	Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2905-2913.	1.9	115
117	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 294-305.	1.1	114
118	TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2103-2112.	1.9	111
119	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 191-200.	5.1	111
120	Mutations of epigenetic regulatory genes are common in thymic carcinomas. <i>Scientific Reports</i> , 2014, 4, 7336.	1.6	109
121	Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. <i>European Journal of Cancer</i> , 2003, 39, 1271-1276.	1.3	107
122	Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling. <i>Molecular Pharmacology</i> , 2005, 68, 502-510.	1.0	107
123	Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. <i>BMC Cancer</i> , 2006, 6, 129.	1.1	105
124	Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target. <i>PLoS ONE</i> , 2008, 3, e0001722.	1.1	105
125	The immunoregulatory role of CD1d-restricted natural killer T cells in disease. <i>Clinical Immunology</i> , 2004, 112, 8-23.	1.4	104
126	Histone deacetylase inhibitors in cancer therapy. <i>Current Opinion in Oncology</i> , 2008, 20, 639-649.	1.1	104



#	ARTICLE	IF	CITATIONS
127	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S81-S87.	0.5	104
128	Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. <i>Clinical Cancer Research</i> , 2012, 18, 2099-2107.	3.2	103
129	Reinduction chemotherapy in small cell lung cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1697-1699.	0.9	102
130	Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer "Lung Cancer Group Phase III Trial" 08923. <i>Journal of Clinical Oncology</i> , 2002, 20, 3947-3955.	0.8	102
131	Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1270-1273.	0.5	101
132	Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. <i>Frontiers in Oncology</i> , 2015, 5, 113.	1.3	100
133	Archival Fine-Needle Aspiration Cytopathology (FNAC) Samples. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 739-745.	1.2	97
134	CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants. , 1997, 70, 335-340.		96
135	p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 1996, 74, 63-68.	2.9	95
136	Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. <i>Annals of Oncology</i> , 2001, 12, 1359-1368.	0.6	95
137	Potent expansion of human natural killer T cells using $\alpha$ -galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. <i>Journal of Immunological Methods</i> , 2001, 247, 61-72.	0.6	95
138	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000, 95, 2440-2442.	0.6	94
139	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 95.	3.5	94
140	Morbidity and mortality in the surgery arm of EORTC 08941 trial. <i>European Respiratory Journal</i> , 2005, 26, 192-197.	3.1	93
141	Src as a potential therapeutic target in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2008, 19, 1219-1223.	0.6	92
142	Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. <i>Radiotherapy and Oncology</i> , 1998, 46, 29-32.	0.3	91
143	Quantitative PET imaging of Met-expressing human cancer xenografts with <sup>89</sup> Zr-labelled monoclonal antibody DN30. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1857-1867.	3.3	90
144	LAMC2 enhances the metastatic potential of lung adenocarcinoma. <i>Cell Death and Differentiation</i> , 2015, 22, 1341-1352.	5.0	89

#	ARTICLE	IF	CITATIONS
145	Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2001, 12, 799-805.	0.6	87
146	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 388-394.	0.6	87
147	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1 Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
148	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. <i>Journal of Clinical Investigation</i> , 2014, 124, 3003-3015.	3.9	84
149	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. , 1997, 71, 787-795.		83
150	Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). <i>European Journal of Cancer</i> , 2008, 44, 19-24.	1.3	83
151	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2014, 20, 5392-5402.	3.2	83
152	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2014, 9, 144-153.	0.5	83
153	Thymoma: Update for the New Millenium. <i>Oncologist</i> , 2001, 6, 239-246.	1.9	82
154	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2008, 19, 1605-1612.	0.6	81
155	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 1239-1258.	5.0	81
156	Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. <i>Clinical Cancer Research</i> , 2002, 8, 596-606.	3.2	81
157	Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. <i>British Journal of Cancer</i> , 2000, 83, 1069-1076.	2.9	80
158	P-Glycoprotein A Marker of Cancer-Cell Behavior. <i>New England Journal of Medicine</i> , 1995, 333, 1417-1419.	13.9	79
159	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. <i>British Journal of Cancer</i> , 1996, 74, 961-963.	2.9	78
160	EGFR inhibitors: what have we learned from the treatment of lung cancer?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 554-561.	4.3	77
161	A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2010, 16, 1915-1923.	3.2	77
162	The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1467-1473.	0.5	76

#	ARTICLE	IF	CITATIONS
163	Determinants of CPT-11 and SN-38 activities in human lung cancer cells. <i>British Journal of Cancer</i> , 1998, 77, 2171-2176.	2.9	75
164	The multilayered postconfluent cell culture as a model for drug screening. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 36, 141-157.	2.0	75
165	Gemcitabine radiotherapy in patients with locally advanced pancreatic cancer. <i>European Journal of Cancer</i> , 2002, 38, 1212-1217.	1.3	75
166	Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 1654-1660.	0.6	74
167	Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. <i>BMC Cancer</i> , 2009, 9, 180.	1.1	73
168	EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. <i>Modern Pathology</i> , 2012, 25, 548-555.	2.9	73
169	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 693-699.	0.6	73
170	The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. <i>European Radiology</i> , 2007, 17, 1700-1713.	2.3	72
171	STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1466-76.	2.3	72
172	Multidrug resistance proteins and other drug transport-related resistance to natural product agents. <i>Current Opinion in Oncology</i> , 1995, 7, 532-540.	1.1	69
173	Prognostic relevance of P-glycoprotein expression in breast cancer. <i>Annals of Oncology</i> , 1995, 6, 679-685.	0.6	69
174	Uncoupling the Central Spindle-associated Function of the Chromosomal Passenger Complex from Its Role at Centromeres. <i>Molecular Biology of the Cell</i> , 2006, 17, 1897-1909.	0.9	69
175	Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 1435-1442.	0.8	69
176	Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). <i>European Journal of Cancer</i> , 2008, 44, 25-29.	1.3	69
177	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2011, 37, 456-64.	3.4	69
178	How should we analyse FDG PET studies for monitoring tumour response?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 16-21.	3.3	67
179	Association of Polymorphisms in <i>AKT1</i> and <i>EGFR</i> with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 581-593.	1.9	67
180	Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib. <i>Clinical Cancer Research</i> , 2011, 17, 1190-1199.	3.2	67

#	ARTICLE	IF	CITATIONS
181	Neuroendocrine ACTH-Producing Tumor of the Thymus—Experience with 12 Patients over 25 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2223-2230.	1.8	67
182	Second-line chemotherapy and its evaluation in small cell lung cancer. <i>Cancer Treatment Reviews</i> , 1999, 25, 199-206.	3.4	66
183	Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Oncologist</i> , 2003, 8, 576-586.	1.9	66
184	A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 587-596.	1.1	66
185	Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019, 14, 914-923.	0.5	66
186	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	0.8	66
187	Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt346.	3.0	65
188	Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Ad <sup>CMV</sup> 24-p53 against Human Malignant Glioma. <i>Cancer Research</i> , 2004, 64, 5753-5759.	0.4	64
189	Biology and management of malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2006, 42, 2706-2714.	1.3	64
190	The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1961-1970.	3.2	64
191	Next generation oncology drug development: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 259-265.	12.5	64
192	The Role of Gefitinib in Lung Cancer Treatment. <i>Clinical Cancer Research</i> , 2004, 10, 4233s-4237s.	3.2	64
193	MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e21300.	1.1	64
194	Expression and localization of inhibitor of apoptosis proteins in normal human tissues. <i>Human Pathology</i> , 2006, 37, 78-86.	1.1	63
195	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011, 12, 159-170.	0.6	63
196	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. <i>Cell Death and Disease</i> , 2012, 3, e351-e351.	2.7	63
197	MEK inhibitors under development for treatment of non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 17-30.	1.9	63
198	Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1995, 13, 660-665.	0.8	62

#	ARTICLE	IF	CITATIONS
199	The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2003, 39, 353-357.	1.3	62
200	Cancer of the esophagus and gastric cardia: recent advances*. <i>Ecological Management and Restoration</i> , 2004, 17, 10-26.	0.2	62
201	Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. <i>Journal of Clinical Oncology</i> , 1992, 10, 824-828.	0.8	61
202	MDR1/P-glycoprotein expression in colorectal cancer. <i>European Journal of Cancer</i> , 1995, 31, 1291-1294.	1.3	61
203	Topoisomerase III± and other drug resistance markers in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 32, 117-128.	0.9	61
204	Expression and Mutational Status of c-kit in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1447-1453.	0.5	61
205	DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. <i>British Journal of Cancer</i> , 1995, 72, 917-921.	2.9	60
206	Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. <i>Annals of Oncology</i> , 2009, 20, 182-187.	0.6	60
207	From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. <i>Annals of Oncology</i> , 2013, 24, 577-585.	0.6	60
208	Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. <i>Cell Death and Differentiation</i> , 2020, 27, 2143-2157.	5.0	60
209	Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1995, 1264, 337-346.	2.4	59
210	Drug Resistance. <i>Oncologist</i> , 1996, 1, 82-87.	1.9	59
211	5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. <i>Annals of Oncology</i> , 2001, 12, 209-216.	0.6	59
212	Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. <i>Cancer</i> , 2010, 116, 4686-4695.	2.0	59
213	A population-based assessment of mortality and morbidity patterns among patients with thymoma. <i>International Journal of Cancer</i> , 2011, 128, 2688-2694.	2.3	59
214	Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. <i>Cancer Research</i> , 2003, 63, 4101-6.	0.4	59
215	Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. <i>Annals of Oncology</i> , 2005, 16, 1695-1701.	0.6	58
216	Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 261.	1.3	58

#	ARTICLE	IF	CITATIONS
217	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. <i>Journal of Molecular Medicine</i> , 2014, 92, 697-707.	1.7	58
218	Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling. <i>Clinical Cancer Research</i> , 2015, 21, 4508-4513.	3.2	58
219	Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients. <i>Annals of Oncology</i> , 2000, 11, 965-970.	0.6	57
220	Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. <i>European Journal of Cancer</i> , 2003, 39, 1416-1422.	1.3	56
221	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2010, 6, 39-43.	2.5	56
222	Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3659-67.	3.3	56
223	CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. <i>British Journal of Cancer</i> , 1998, 77, 359-365.	2.9	54
224	The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. <i>Trials</i> , 2009, 10, 121.	0.7	54
225	Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2638-2645.	3.2	54
226	Biomarkers in Early-Stage Non-Small-Cell Lung Cancer: Current Concepts and Future Directions. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1609-1617.	0.5	54
227	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 737-747.	0.5	54
228	EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens. <i>Analytical Cellular Pathology</i> , 2007, 29, 257-264.	0.7	53
229	MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung. , 1996, 66, 760-767.		52
230	A phase II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2000, 11, 109-112.	0.6	52
231	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, 63-66.	2.5	52
232	Caelyx,® in malignant mesothelioma: A phase II EORTC study. <i>Annals of Oncology</i> , 2000, 11, 697-700.	0.6	51
233	Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. <i>European Journal of Pharmacology</i> , 2010, 637, 38-45.	1.7	51
234	Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR tyrosine kinase inhibitors. <i>Cancer Science</i> , 2013, 104, 584-589.	1.7	51



#	ARTICLE	IF	CITATIONS
235	Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC lung cancer cooperative group. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1627-1629.	0.9	50
236	Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies. <i>European Journal of Cancer</i> , 2009, 45, 741-746.	1.3	50
237	Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC lung cancer cooperative group. <i>European Journal of Cancer</i> , 1997, 33, 2211-2215.	1.3	49
238	A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 219-225.	0.7	49
239	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. <i>European Journal of Cancer</i> , 2010, 46, 901-911.	1.3	49
240	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 801-809.	0.5	49
241	Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2004, 15, 831-838.	0.6	48
242	A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 3642-3651.	3.2	48
243	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013, 24, 2875-2880.	0.6	48
244	Thymic epithelial tumors: From biology to treatment. <i>Cancer Treatment Reviews</i> , 2020, 86, 102014.	3.4	48
245	Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase iii study of the eortc lung cancer cooperative group. <i>European Journal of Cancer</i> , 1997, 33, 1759-1766.	1.3	47
246	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. <i>Annals of Oncology</i> , 2005, 16, 538-548.	0.6	47
247	Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-“small cell lung cancer cell line NCI-H460. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1046-1053.	1.9	47
248	Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy. <i>Current Molecular Medicine</i> , 2012, 12, 1125-1141.	0.6	47
249	Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. <i>Annals of Oncology</i> , 2006, 17, 35-42.	0.6	46
250	The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 436-447.	0.5	46
251	Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. <i>Annals of Oncology</i> , 1996, 7, 625-630.	0.6	45
252	A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). <i>Lung Cancer</i> , 2005, 50, 91-96.	0.9	45

#	ARTICLE	IF	CITATIONS
253	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. <i>Cell Cycle</i> , 2011, 10, 3119-3128.	1.3	45
254	Clinical impact of novel treatment strategies. <i>Oncogene</i> , 2002, 21, 6970-6981.	2.6	44
255	Treatment of malignant thymoma. <i>Current Opinion in Oncology</i> , 2005, 17, 140-146.	1.1	44
256	Dose-Finding Study of the Multitargeted Tyrosine Kinase Inhibitor SU6668 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2005, 11, 6240-6246.	3.2	44
257	Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: A small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. <i>Experimental Cell Research</i> , 2007, 313, 1215-1224.	1.2	44
258	Phase I study of the <sup>177</sup> Lu-DOTA-Tyr <sup>3</sup> -Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. , 2020, 8, e000980.		44
259	Clinical resistance to topoisomerase-targeted drugs. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998, 1400, 275-288.	2.4	43
260	Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydropyridine (molar ratio 1:0.4:1) in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 1-12.	1.1	43
261	Angiogenesis Inhibitors. Drug Selectivity and Target Specificity. <i>Current Pharmaceutical Design</i> , 2007, 13, 2795-2809.	0.9	43
262	Homodimerization Antagonizes Nuclear Export of Survivin. <i>Traffic</i> , 2007, 8, 1495-1502.	1.3	43
263	PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1345-1356.	0.5	43
264	TWO SUDDEN DEATHS DURING PROPHYLACTIC ANTIEMETIC TREATMENT WITH HIGH DOSES OF DOMPERIDONE AND METHYLPREDNISOLONE. <i>Lancet, The</i> , 1984, 324, 1336-1337.	6.3	42
265	The determination of gemcitabine and 2-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 847, 142-152.	1.2	42
266	HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. <i>Oncogene</i> , 2014, 33, 4867-4876.	2.6	42
267	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. <i>Cancer Genetics</i> , 2017, 218-219, 39-50.	0.2	42
268	Multidrug resistance from the clinical point of view. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1481-1486.	0.9	41
269	Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. <i>European Journal of Cancer</i> , 2005, 41, 1560-1569.	1.3	41
270	Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab. <i>Journal of Clinical Oncology</i> , 2010, 28, e507-e510.	0.8	41

#	ARTICLE	IF	CITATIONS
271	Cross-resistance in the 2â€²,2â€²-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. <i>European Journal of Cancer</i> , 2000, 36, 1974-1983.	1.3	40
272	Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. <i>Annals of Oncology</i> , 2004, 15, 59-63.	0.6	40
273	Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1032-1045.	0.5	40
274	Systemic Treatment of Malignant Thymoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 336-344.	0.6	39
275	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008, 44, 2178-2184.	1.3	39
276	Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. <i>British Journal of Cancer</i> , 2009, 100, 145-152.	2.9	39
277	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. <i>Anti-Cancer Drugs</i> , 2018, 29, 457-465.	0.7	39
278	&lt;p&gt;Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3187-3198.	2.0	39
279	A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8019-8019.	0.8	39
280	Treatment of Advanced Thymoma and Thymic Carcinoma. <i>Current Treatment Options in Oncology</i> , 2008, 9, 277-287.	1.3	38
281	Lung Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 302-308.	1.0	38
282	Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 1960-1971.	3.2	38
283	MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: Alterations in cellular pharmacokinetics and in pattern of cross-resistance. <i>International Journal of Cancer</i> , 1995, 62, 84-89.	2.3	37
284	Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. <i>Experimental Cell Research</i> , 2004, 298, 535-548.	1.2	37
285	Drug Development: Portals of Discovery. <i>Clinical Cancer Research</i> , 2012, 18, 23-32.	3.2	37
286	Reproducibility of the WHO classification of thymomas: Practical implications. <i>Lung Cancer</i> , 2013, 79, 236-241.	0.9	37
287	Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 247-253.	0.9	37
288	Targeted agents: How to select the winners in preclinical and early clinical studies?. <i>European Journal of Cancer</i> , 2012, 48, 170-178.	1.3	36

#	ARTICLE	IF	CITATIONS
289	Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. <i>Journal of Thoracic Oncology</i> , 2021, 16, 483-485.	0.5	36
290	Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. <i>Biochemical Pharmacology</i> , 1994, 47, 1325-1332.	2.0	35
291	Oncogenes and Antioncogenes in Lung Tumorigenesis. <i>Chest</i> , 1996, 109, 130S-134S.	0.4	35
292	Targeting the Immune System in Nonâ€“Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality. <i>Clinical Lung Cancer</i> , 2010, 11, 228-237.	1.1	35
293	Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. <i>Lung Cancer</i> , 2010, 68, 154-160.	0.9	35
294	Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. <i>Oncogene</i> , 2011, 30, 1744-1752.	2.6	35
295	Why has active immunotherapy not worked in lung cancer?. <i>Annals of Oncology</i> , 2015, 26, 2213-2220.	0.6	35
296	A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2002, 38, 779-783.	1.3	34
297	Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. <i>Oncogene</i> , 2006, 25, 4867-4879.	2.6	34
298	Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. <i>European Journal of Cancer</i> , 1993, 29, 1566-1573.	1.3	33
299	The role of new agents in the treatment of non-small cell lung cancer. <i>European Journal of Cancer</i> , 2002, 38, 2347-2361.	1.3	33
300	Population pharmacokinetics of the novel anticancer agent KRN7000. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 287-293.	1.1	33
301	Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. <i>Cancer Gene Therapy</i> , 2004, 11, 539-546.	2.2	33
302	Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, 414-418.	0.5	33
303	Effects of Î±-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human VÎ±24+ â€“VÎ²11+ T cells. <i>Immunology</i> , 1999, 98, 557-563.	2.0	32
304	The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. <i>Oncogene</i> , 2004, 23, 9102-9110.	2.6	32
305	Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. <i>Proteome Science</i> , 2009, 7, 34.	0.7	32
306	Acupuncture Treatment for Persistent Hiccups in Patients with Cancer. <i>Journal of Alternative and Complementary Medicine</i> , 2010, 16, 811-816.	2.1	32

#	ARTICLE	IF	CITATIONS
307	Chemotherapy for Thymic Tumors: Induction, Consolidation, Palliation. <i>Thoracic Surgery Clinics</i> , 2011, 21, 107-114.	0.4	32
308	Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1397-1403.	1.1	32
309	Tyrosine Kinase Inhibitors in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 589-605.	0.9	32
310	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 720-726.	1.3	32
311	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Oncology Practice</i> , 2016, 12, 83-86.	2.5	32
312	Severe acute lung injury induced by gemcitabine. <i>Netherlands Journal of Medicine</i> , 2000, 56, 232-235.	0.6	31
313	Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. <i>British Journal of Cancer</i> , 2004, 91, 171-177.	2.9	31
314	Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. <i>Proteomics - Clinical Applications</i> , 2007, 1, 598-604.	0.8	31
315	EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer. <i>Molecular Oncology</i> , 2016, 10, 601-609.	2.1	31
316	Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. <i>Cancer Research</i> , 2017, 77, 5614-5627.	0.4	31
317	Travoprost: A potent ocular hypotensive agent. <i>Drugs of Today</i> , 2003, 39, 61.	2.4	31
318	Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase iii trial. <i>European Journal of Cancer</i> , 1996, 32, 1498-1503.	1.3	30
319	Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human $\text{V}\alpha 24+\text{V}\beta 11+$ T cells in vitro. <i>Human Immunology</i> , 2000, 61, 357-365.	1.2	30
320	Novel approaches to the treatment of non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 57-77.	2.0	30
321	Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. <i>Annals of Oncology</i> , 2004, 15, 230-235.	0.6	30
322	Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2004, 40, 667-672.	1.3	30
323	Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. <i>Human Molecular Genetics</i> , 2005, 14, 1271-1281.	1.4	30
324	Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 739-744.	0.9	29

#	ARTICLE	IF	CITATIONS
325	Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. <i>European Journal of Cancer</i> , 2000, 36, 2420-2429.	1.3	29
326	Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. <i>Histopathology</i> , 2007, 51, 631-637.	1.6	29
327	Downregulation of <sup>18</sup> F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non-Small Cell Lung Cancer with the mTOR Inhibitor Everolimus. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1815-1819.	2.8	29
328	Whole Genome and Transcriptome Sequencing of a B3 Thymoma. <i>PLoS ONE</i> , 2013, 8, e60572.	1.1	28
329	Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 567-571.	0.5	28
330	Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1996, 14, 127-134.	0.8	27
331	A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. <i>British Journal of Cancer</i> , 2002, 86, 1230-1234.	2.9	27
332	Heat Shock Protein 90-Sheltered Overexpression of Insulin-Like Growth Factor 1 Receptor Contributes to Malignancy of Thymic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 2237-2249.	3.2	27
333	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. <i>Future Oncology</i> , 2005, 1, 449-460.	1.1	26
334	A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. <i>Clinical Cancer Research</i> , 2007, 13, 3906-3912.	3.2	26
335	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-Small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 7467-7473.	3.2	26
336	Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. <i>European Journal of Cancer</i> , 2018, 99, 37-48.	1.3	26
337	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. <i>Journal of Thoracic Oncology</i> , 2007, 2, 12-21.	0.5	26
338	Second line chemotherapy in small cell lung cancer. <i>Lung Cancer</i> , 1989, 5, 207-213.	0.9	25
339	Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. <i>British Journal of Cancer</i> , 1992, 66, 660-665.	2.9	25
340	Small-molecule inhibitors of the human epidermal receptor family. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1829-1842.	1.9	25
341	Phase I trial of SU14813 in patients with advanced solid malignancies. <i>Annals of Oncology</i> , 2011, 22, 195-201.	0.6	25
342	Treatment of nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 123-129.	1.1	25



#	ARTICLE	IF	CITATIONS
343	Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2601-2613.	1.9	25
344	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 1487-1493.	3.2	25
345	Teniposide (VM26): An effective treatment for brain metastases of small cell carcinoma of the lung. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 629-631.	0.9	24
346	Targeted Therapy for Advanced Thymic Tumors. <i>Journal of Thoracic Oncology</i> , 2010, 5, S361-S364.	0.5	24
347	HER2 Mutations in Non-Small-Cell Lung Cancer Can Be Continually Targeted. <i>Journal of Clinical Oncology</i> , 2012, 30, 3318-3319.	0.8	24
348	The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2013, 19, 6777-6786.	3.2	24
349	Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1985, 21, 433-437.	0.9	23
350	Current chemotherapeutic possibilities in pancreaticobiliary cancer. <i>Annals of Oncology</i> , 1999, 10, S157-S161.	0.6	23
351	Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. <i>British Journal of Cancer</i> , 2005, 92, 882-887.	2.9	23
352	Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. <i>Journal of Proteomics</i> , 2009, 72, 575-585.	1.2	23
353	Endothelial Dysfunction in Antiangiogenesis-Associated Thrombosis. <i>Journal of Clinical Oncology</i> , 2002, 20, 3042-3043.	0.8	22
354	Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). <i>Annals of Oncology</i> , 2003, 14, 248-257.	0.6	22
355	Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?. <i>Current Opinion in Oncology</i> , 2005, 17, 392-396.	1.1	22
356	Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity. <i>Clinical Cancer Research</i> , 2006, 12, 1760-1767.	3.2	22
357	Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. <i>Molecular Cancer</i> , 2007, 6, 56.	7.9	22
358	Antiangiogenic therapy in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2008, 20, 176-182.	1.1	22
359	Emerging protein kinase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 51-65.	1.0	22
360	Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 108-116.	0.9	22

#	ARTICLE	IF	CITATIONS
361	Treatment of metastatic non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 1996, 8, 120-125.	1.1	21
362	Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor. <i>Clinical and Developmental Immunology</i> , 2007, 2007, 1-9.	3.3	21
363	Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. <i>Annals of Oncology</i> , 2009, 20, 1565-1575.	0.6	21
364	Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 524-533.	3.2	21
365	High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 38-45.	0.9	21
366	Precision oncology in non-small-cell lung cancer: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 348-349.	12.5	21
367	Concurrent Molecular Alterations in Tumors With Germ Line Epidermal Growth Factor Receptor T790M Mutations. <i>Clinical Lung Cancer</i> , 2013, 14, 452-456.	1.1	20
368	Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2263-2279.	5.0	20
369	The costâ€™ effectiveness of paclitaxel (Taxol)+ cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 1999, 10, 605-616.	0.7	19
370	Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: Single-centre experience in 145 patients. <i>Annals of Oncology</i> , 2000, 11, 1563-1570.	0.6	19
371	Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). <i>European Journal of Cancer</i> , 2006, 42, 1399-1406.	1.3	19
372	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. <i>Journal of Thoracic Oncology</i> , 2007, 2, 12-21.	0.5	19
373	Response to Crizotinib in <i>ROS1</i>-Rearranged Nonâ€™Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3425-3426.	0.8	19
374	Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement. <i>Journal of Thoracic Oncology</i> , 2012, 7, e29-e31.	0.5	19
375	Molecular predictors of response to pembrolizumab in thymic carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100392.	3.3	19
376	Ongoing and future trials of biologic therapies in lung cancer. <i>Lung Cancer</i> , 2003, 41, 175-186.	0.9	18
377	Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. <i>Experimental Cell Research</i> , 2003, 286, 381-395.	1.2	18
378	Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2004, 15, 484-488.	0.6	18

#	ARTICLE	IF	CITATIONS
379	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. <i>Journal of Thoracic Oncology</i> , 2006, 1, S32-S36.	0.5	18
380	Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of the Results of a Multicenter, Randomized, Controlled Trial Based on Initial Hemoglobin Level. <i>Oncologist</i> , 2006, 11, 206-216.	1.9	18
381	A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. <i>European Journal of Cancer</i> , 2009, 45, 2519-2527.	1.3	18
382	NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2012, 7, 744-750.	0.5	18
383	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001263.	0.5	18
384	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016, 101, 104-110.	0.9	18
385	Effects of tumor necrosis factor, alone or in combination with topoisomerase-ii-targeted drugs, on human lung cancer cell lines. <i>International Journal of Cancer</i> , 1990, 46, 326-329.	2.3	17
386	Multimodality treatment of malignant germ cell tumours of the mediastinum. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 273-277.	0.9	17
387	Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. <i>British Journal of Cancer</i> , 2001, 85, 1456-1461.	2.9	17
388	The role of talactoferrin alfa in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1379-1386.	1.4	17
389	Semiautomated Laser Capture Microdissection of Lung Adenocarcinoma Cytology Samples. <i>Acta Cytologica</i> , 2012, 56, 622-631.	0.7	17
390	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology: Erratum. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1343.	0.5	17
391	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. <i>PLoS ONE</i> , 2018, 13, e0208097.	1.1	17
392	Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8026-8026.	0.8	17
393	The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report. <i>Lung Cancer</i> , 1989, 5, 135-138.	0.9	16
394	Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 1997, 8, 957-962.	0.6	16
395	Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. <i>Biochemical Journal</i> , 2003, 373, 251-259.	1.7	16
396	FANCD2 Expression in Advanced Non-Small-Cell Lung Cancer and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2005, 6, 250-254.	1.1	16

#	ARTICLE	IF	CITATIONS
397	EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 296-297.	4.3	16
398	Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. <i>Journal of Clinical Pathology</i> , 2005, 58, 695-699.	1.0	16
399	The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. <i>Molecular Cancer</i> , 2007, 6, 73.	7.9	16
400	Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1267-1273.	0.5	16
401	Identification of new drugs in pretreated patients with small cell lung cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 411-413.	0.9	15
402	Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. <i>Biochemical Pharmacology</i> , 1994, 48, 1145-1154.	2.0	15
403	New drugs in non-small cell lung cancer. An overview. <i>Lung Cancer</i> , 1995, 12, S155-S162.	0.9	15
404	Chemotherapy. <i>Lancet</i> , The, 1997, 349, S7-S9.	6.3	15
405	The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 4072-4076.	3.2	15
406	Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. <i>British Journal of Cancer</i> , 2005, 92, 1636-1643.	2.9	15
407	Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC). <i>Current Drug Targets</i> , 2010, 11, 12-28.	1.0	15
408	<i>EGFR</i> Mutations in Latinos From the United States and Latin America. <i>Journal of Global Oncology</i> , 2016, 2, 259-267.	0.5	15
409	Epirubicin in previously untreated patients with small cell lung cancer: A phase II study by the EORTC lung cancer cooperative group. <i>European Journal of Cancer</i> , 1992, 28, 1667-1670.	1.3	14
410	Effects of suramin on human lung cancer cell lines. <i>European Journal of Cancer</i> , 1995, 31, 244-251.	1.3	14
411	Hepatic Arterial Chemotherapy for Colorectal Cancer Metastatic to the Liver. <i>Oncology</i> , 2000, 59, 89-97.	0.9	14
412	Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. <i>Seminars in Oncology</i> , 2002, 29, 47-49.	0.8	14
413	Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 509-516.	1.1	14
414	Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1026-1036.	1.9	14

#	ARTICLE	IF	CITATIONS
415	Characterization and Management of Cardiac Involvement of Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 246-249.	0.5	14
416	An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. <i>Hepatology</i> , 2018, 67, 159-170.	3.6	14
417	Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology. <i>Frontiers in Oncology</i> , 2021, 11, 642112.	1.3	14
418	Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. <i>Clinical Lung Cancer</i> , 2022, 23, e238-e242.	1.1	14
419	Twenty-five years of treating advanced NSCLC: what have we achieved?. <i>Annals of Oncology</i> , 2004, 15, iv81-iv83.	0.6	13
420	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. <i>Journal of Thoracic Oncology</i> , 2006, 1, S32-S36.	0.5	13
421	Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. <i>International Journal of Oncology</i> , 2010, 37, 963-71.	1.4	13
422	Next-Generation Sequencing: Targeting Targeted Therapies. <i>Clinical Cancer Research</i> , 2015, 21, 3584-3585.	3.2	13
423	A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 64.	1.3	13
424	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 247-257.	1.3	13
425	Downregulation of CYLD promotes IFN- $\gamma$ mediated PD-L1 expression in thymic epithelial tumors. <i>Lung Cancer</i> , 2020, 147, 221-228.	0.9	13
426	Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 1987, 56, 475-478.	2.9	12
427	Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell Lung Cancer in a randomised phase II study. <i>European Journal of Cancer</i> , 1992, 28, 96-100.	1.3	12
428	Multidrug resistance in breast cancer: Mechanisms, strategies. <i>European Journal of Cancer</i> , 1995, 31, S15-S17.	1.3	12
429	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. <i>Oncology Letters</i> , 2015, 10, 1155-1158.	0.8	12
430	IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21623-e21623.	0.8	12
431	The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 838-851.	0.5	12
432	Stevens-Johnson Syndrome and Fatal Pulmonary Toxicity to Combination Chemotherapy Containing Bleomycin: A Case Report. <i>Tumori</i> , 1986, 72, 331-333.	0.6	11

#	ARTICLE	IF	CITATIONS
433	Pancreaticobiliary cancer: The future aspects of medical oncology. <i>Annals of Oncology</i> , 1999, 10, S296-S299.	0.6	11
434	Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. <i>Lung Cancer</i> , 2001, 33, 267-275.	0.9	11
435	Fluorouracil (5FU) Pharmacokinetics in 5FU Prodrug Formulations With a Dihydropyrimidine Dehydrogenase Inhibitor. <i>Journal of Clinical Oncology</i> , 2001, 19, 4267-4269.	0.8	11
436	TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. <i>BMC Cancer</i> , 2006, 6, 166.	1.1	11
437	Response to Erlotinib in First-Line Treatment of Non-Small-Cell Lung Cancer in a White Male Smoker with Squamous-Cell Histology. <i>Clinical Lung Cancer</i> , 2006, 8, 214-216.	1.1	11
438	International Thymic Malignancy Interest Group. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1-2.	0.5	11
439	Multiorgan Autoimmune Manifestations Associated with Thymoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e5-e7.	0.5	11
440	Phase II trial of sunitinib in patients with thymic epithelial tumors (TET).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7525-7525.	0.8	11
441	A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7526-7526.	0.8	11
442	CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 29199-29210.	0.8	11
443	Bone Marrow Evaluation in Small Cell Carcinoma of the Lung. <i>Acta Oncologica</i> , 1987, 26, 185-188.	0.8	10
444	Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial. <i>Lancet</i> , The, 1994, 343, 1648-1649.	6.3	10
445	Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?. <i>European Journal of Cancer</i> , 1998, 34, 1993-1995.	1.3	10
446	Natural Killer T cells. <i>Lancet Oncology</i> , The, 2002, 3, 574.	5.1	10
447	Medical treatment of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, ii229-ii232.	0.6	10
448	Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. <i>European Journal of Cancer</i> , 2006, 42, 1391-1398.	1.3	10
449	Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared with Population Normative Data. <i>Oncologist</i> , 2006, 11, 197-205.	1.9	10
450	Acute Autoimmune Hepatitis, Myositis, and Myasthenic Crisis in a Patient with Thymoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, e87-e88.	0.5	10



#	ARTICLE	IF	CITATIONS
451	30 Immunotherapy in advanced NSCLCâ€”from the â€”tsunamiâ€” of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	2.0	10
452	Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1187-1201.	1.3	10
453	Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 909-910.	0.9	9
454	Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells. <i>British Journal of Cancer</i> , 1992, 66, 488-495.	2.9	9
455	Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: A randomized phase II trial of the EORTC lung cancer cooperative group. <i>Annals of Oncology</i> , 1996, 7, 637-639.	0.6	9
456	Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. <i>British Journal of Cancer</i> , 1998, 78, 1586-1593.	2.9	9
457	Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens. <i>Clinical Drug Investigation</i> , 1998, 15, 327-335.	1.1	9
458	Cremonophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol <sup>Â®</sup> ) and carboplatin in non-small cell lung cancer patients. <i>Anti-Cancer Drugs</i> , 2000, 11, 687-694.	0.7	9
459	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 467-476.	1.2	9
460	Thymoma-Associated Paraneoplastic Polymyositis. <i>Journal of Clinical Oncology</i> , 2010, 28, e378-e378.	0.8	9
461	Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2013, 49, 1808-1814.	1.3	9
462	Effect of Talactoferrin Alfa on the Immune System in Adults With Nonâ€”Small Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 821-822.	1.9	9
463	CYB5A and autophagy-mediated cell death in pancreatic cancer. <i>Autophagy</i> , 2014, 10, 697-698.	4.3	9
464	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. <i>Lung Cancer</i> , 2017, 112, 195-199.	0.9	9
465	A Phase I Trial of Dasatinib and Osimertinib in TKI Na <sup>Â</sup> ve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 728155.	1.3	9
466	Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. <i>Annals of Translational Medicine</i> , 2016, 4, 466-466.	0.7	9
467	Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers. <i>Lung Cancer</i> , 2021, 162, 23-28.	0.9	9
468	4?-epi-doxorubicin in advanced lung cancer. <i>Investigational New Drugs</i> , 1990, 8, 393-6.	1.2	8

#	ARTICLE	IF	CITATIONS
469	Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34+precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. <i>Immunotherapy</i> , 2011, 3, 1051-1061.	1.0	8
470	Phase II study of ACNU as second-line treatment in small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 29, 409-411.	1.1	7
471	A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. <i>Annals of Oncology</i> , 2001, 12, 1567-1573.	0.6	7
472	Genotype analysis of the VNTR polymorphism in the <i>SMYD3</i> histone methyltransferase gene: Lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. <i>International Journal of Cancer</i> , 2008, 122, 1441-1442.	2.3	7
473	DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens. <i>Current Drug Metabolism</i> , 2011, 12, 956-965.	0.7	7
474	Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection. <i>Translational Lung Cancer Research</i> , 2012, 1, 230-3.	1.3	7
475	Comparison of Methylprednisolone and Metoclopramide in the Prophylactic Treatment of CIS-Platin-Induced Nausea and Vomiting. <i>Tumori</i> , 1984, 70, 237-241.	0.6	6
476	Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 145-146.	1.1	6
477	<sup>18</sup> Fluorodeoxyglucose Positron Emission Tomography, a Standard Diagnostic Tool in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1741-1743.	3.0	6
478	Effect of Food on the Pharmacokinetic Behavior of the Potent Oral Taxane BMS-275183. <i>Clinical Cancer Research</i> , 2008, 14, 4186-4191.	3.2	6
479	Refining standard practice and admitting uncertainty. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 69-70.	12.5	6
480	Genomics-based early-phase clinical trials in oncology: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2014, 50, 2747-2751.	1.3	6
481	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019, 14, e0212097.	1.1	6
482	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) <sub>n</sub> Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 896.	1.8	6
483	First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3081-3081.	0.8	6
484	A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7103-7103.	0.8	6
485	Safety and activity of Combined AVELumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e211114-e211114.	0.8	6
486	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6

#	ARTICLE	IF	CITATIONS
487	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000, 95, 2440-2442.	0.6	6
488	The differential diagnosis of primary lung cancer: Inter-observer agreement and contribution of specific diagnostic procedures. <i>Journal of Clinical Epidemiology</i> , 1992, 45, 827-833.	2.4	5
489	Treatment of thymoma and thymic carcinoma. <i>Annals of Oncology</i> , 2000, 11, 245-246.	0.6	5
490	Signal Transduction Modulators for Cancer Therapy: From Promise to Practice?. <i>Oncologist</i> , 2003, 8, 210-213.	1.9	5
491	Newer opportunities in systemic therapy of lung cancer. <i>Annals of Oncology</i> , 2008, 19, vii31-vii37.	0.6	5
492	Importance of patient selection for EGFR TKIs in lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 360-362.	12.5	5
493	First-line immunotherapy in lung cancer â€” taking the first step. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 595-596.	12.5	5
494	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. <i>Cancer Genetics</i> , 2018, 228-229, 131-142.	0.2	5
495	Lung cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 445-483.	0.5	5
496	Phase II study of cixutumumab (IMC-A12) in thymic malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7033-7033.	0.8	5
497	Chest Irradiation as an Attempt to Improve the Response After Induction Chemotherapy in Small Cell Lung Carcinoma. <i>Acta Radiologica Oncology</i> , 1985, 24, 475-479.	0.5	4
498	4â€²-deoxydoxorubicin, an inactive drug in small cell lung cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1407-1408.	0.9	4
499	Exercise-induced spontaneous hemothorax insinuates trauma; yet unmasks a lament disorder. <i>Netherlands Journal of Medicine</i> , 2001, 59, 292-294.	0.6	4
500	Analysis of Deoxycytidine Accumulation in Gemcitabine Treated Patients. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2006, 25, 1225-1232.	0.4	4
501	Immunohistochemical detection of nuclear survivin in NSCLC: a comparison of commercial antibodies. <i>Histopathology</i> , 2007, 50, 671-675.	1.6	4
502	Challenges in Cancer Molecular Targets and Therapeutics. <i>Frontiers in Oncology</i> , 2011, 1, 4.	1.3	4
503	Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small) Tj ETQq1 1 0.784314 rgBT /Overloc 0.8 4	0.8	4
504	Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9594-9594.	0.8	4

#	ARTICLE	IF	CITATIONS
505	Phase II study of divided-dose vinblastine in advanced breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 21, 65-7.	1.1	3
506	In vitro sequence-dependent synergistic effect of suramin and camptothecin. <i>European Journal of Cancer</i> , 1994, 30, 1670-1674.	1.3	3
507	State of the art in systemic treatment of lung cancer. <i>European Journal of Cancer</i> , 2001, 37, 99-114.	1.3	3
508	Clinical potential of proteasome inhibition in solid tumours. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 25-28.	2.2	3
509	Keynote comment: Are large-scale cancer-genomics projects ready to use?. <i>Lancet Oncology</i> , The, 2006, 7, 190-191.	5.1	3
510	Iron Absorption During Epoetin Alfa Therapy for Chemotherapy-Associated Anaemia. <i>Cancer Investigation</i> , 2006, 24, 562-566.	0.6	3
511	Met amplification and HSP90 inhibitors. <i>Cell Cycle</i> , 2009, 8, 2681-2684.	1.3	3
512	Foreword. <i>Journal of Thoracic Oncology</i> , 2010, 5, S259.	0.5	3
513	Ganetespib for small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 103-108.	1.9	3
514	Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. <i>Journal of Oncology Practice</i> , 2017, 13, 780-783.	2.5	3
515	Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 145, 48-57.	0.9	3
516	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 245-246.	0.6	3
517	Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8597-TPS8597.	0.8	3
518	Phase II Study of Divided-Dose Vinblastine in Advanced Cancer Patients. <i>Tumori</i> , 1989, 75, 248-251.	0.6	2
519	Pilot study of teniposide in combination chemotherapy for small cell lung cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 141-143.	0.9	2
520	Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1104-1106.	0.9	2
521	10th Conference on DNA Topoisomerases in therapy. <i>Drug Resistance Updates</i> , 1999, 2, 347-350.	6.5	2
522	Chemotherapy for non-small-cell lung cancer. <i>Lancet</i> , The, 2001, 358, 1271.	6.3	2

#	ARTICLE	IF	CITATIONS
523	Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. <i>Acta Oncologica</i> , 2021, 60, 649-652.	0.8	2
524	Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e140-e147.	1.1	2
525	Molecular Pathways of Drug Resistance. , 2004, , 463-489.		2
526	Lung cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 413-442.	0.5	2
527	Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine. <i>British Journal of Cancer</i> , 2022, 126, 754-763.	2.9	2
528	Doxorubicin and Etoposide in the Treatment of Advanced Measurable Breast Cancer. <i>Oncology</i> , 1990, 47, 105-108.	0.9	1
529	A bone biopsy is mandatory in the optimal management of bone lesions in patients with a long-term history of malignancy of the breast. <i>Netherlands Journal of Medicine</i> , 2000, 56, 223-228.	0.6	1
530	Gefitinib does not improve survival when combined with gemcitabine and cisplatin in people with advanced non-small-cell lung cancer. Abstracted from: Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. <i>J Clin Oncol</i> 2004;22:777-784. <i>Cancer Treatment Reviews</i> , 2004, 30, 651-653.	3.4	1
531	The Role of EGFR-TK Inhibition in Non-Small Cell Lung Cancer. <i>Oncology Research and Treatment</i> , 2005, 28, 619-620.	0.8	1
532	Antiangiogenesis Induced Tumor Cavitation in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1573-1575.	0.5	1
533	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3187-3192.	1.2	1
534	Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies. <i>Clinical Investigation</i> , 2012, 2, 133-138.	0.0	1
535	Thymomas: The Need for Prospective Studies. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1230-1231.	0.5	1
536	“Pseudocavitation” in Thymic Carcinoma During Treatment with Sunitinib. <i>Journal of Thoracic Oncology</i> , 2013, 8, 511-512.	0.5	1
537	Novel Treatments for Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2015, 5, 267.	1.3	1
538	What Can We Learn From the French Experience in Systemic Treatment of Thymic Epithelial Tumors?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1623-1624.	0.5	1
539	Best practices and guidelines for the management of thymic epithelial tumors. <i>Mediastinum</i> , 2019, 3, 32-32.	0.6	1
540	Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8577-8577.	0.8	1

#	ARTICLE	IF	CITATIONS
541	The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy. , 2008, , 707-715.		1
542	Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report. Cases Journal, 2009, 2, 6264.	0.4	1
543	Phase II study of KNO46 in patients with thymic carcinoma who failed immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, TPS8607-TPS8607.	0.8	1
544	Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Cancer Chemotherapy and Pharmacology, 1991, 28, 147-149.	1.1	0
545	Ongoing clinical trials in lung cancer. European Journal of Surgical Oncology, 1996, 22, 4-9.	0.5	0
546	Eighth conference on DNA topoisomerases and therapy Amsterdam, The Netherlands 15â€“17 October 1997. Drug Resistance Updates, 1998, 1, 73-75.	6.5	0
547	Introduction. Lung Cancer, 2005, 50, S1-S2.	0.9	0
548	Mesotheliomas. , 2006, , 279-292.		0
549	Grand Challenges in Oncology. Frontiers in Oncology, 2011, 1, 26.	1.3	0
550	Reply to M.C. Garassino et al. Journal of Clinical Oncology, 2011, 29, 3837-3837.	0.8	0
551	MicroRNA Expression and Outcome in Resected NSCLCâ€™Response. Cancer Research, 2011, 71, 5358-5359.	0.4	0
552	Targeted Therapies for Non-Small-Cell Lung Cancer. , 2012, , .		0
553	Reply to A. Stenzinger et al. Journal of Clinical Oncology, 2015, 33, 2824-2824.	0.8	0
554	The role of immune checkpoint blockade for treatment of thymic epithelial tumorsâ€™a delicate balance between efficacy and side effects. Mediastinum, 2018, 2, 39-39.	0.6	0
555	Authorâ€™s Reply. Journal of Thoracic Oncology, 2019, 14, e243-e244.	0.5	0
556	Apoptosis Pathways and New Anticancer Agents. , 2008, , 257-268.		0
557	Platinum Compounds in Lung Cancer: Current Status. , 2009, , 231-242.		0
558	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0



#	ARTICLE	IF	CITATIONS
559	Atezolizumab in lung cancerâ€”appreciating the differences. Translational Cancer Research, 2016, 5, S470-S473.	0.4	0
560	A genomic analysis of large cell neuroendocrine carcinoma versus small cell lung cancer: which is which?. Translational Cancer Research, 2016, 5, S1088-S1092.	0.4	0
561	Response to: intrapulmonary lymph node retrieval. Translational Lung Cancer Research, 2013, 2, E37-8.	1.3	0
562	Quality of life (QoL) of OSE2101 in patients with HLA-A2+ nonâ€”small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.. Journal of Clinical Oncology, 2022, 40, 9094-9094.	0.8	0